ArticleCells2022
Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson's Disease: Preclinical and Clinical Studies.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Effects of microbiome-based interventions on neurodegenerative diseases: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Boswellic acids as an adjunct therapy in Parkinson's disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers.Inflammopharmacology · 2025Trial
- Review
- Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.Pharmacological reports : PR · 2026Review
- A Pilot Longitudinal 16S rRNA Gene Sequencing Study Exploring the Relationship Between Gut Microbiota and Body Composition in Healthy Adults.Polish journal of microbiology · 2026Article
- Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026Review
- "Unfolding Parkinson's Disease Through the Microbiome-Gut-Brain Axis".Journal of molecular neuroscience : MN · 2026Review
- Pharmacological interventions targeting the gut-brain axis in neurological disorders: mechanisms and translational applications.Frontiers in neuroscience · 2026Review
- Article
- Article
- Whole Genome Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- Correlations Between Amelioration of Rotenone-Induced Parkinson's Symptoms byInternational journal of molecular sciences · 2025Article
- Correlation analysis of the impact ofMicrobiology spectrum · 2025Article
- The role of brain-liver-gut Axis in neurological disorders.Burns & trauma · 2025Review
- Annexin A1 levels affect microbiota in health and DSS-induced colitis/inflammatory bowel disease development.Frontiers in immunology · 2025Article
- Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced oxidative stress and inflammation in mice: AnToxicology reports · 2024Article
- The Role of Microbial Metabolites in the Progression of Neurodegenerative Diseases-Therapeutic Approaches: A Comprehensive Review.International journal of molecular sciences · 2024Review
- The Effect of Gut Microbiota-Targeted Interventions on Neuroinflammation and Motor Function in Parkinson's Disease Animal Models-A Systematic Review.Current issues in molecular biology · 2024Review
- Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside.Translational neurodegeneration · 2024Review
- What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson's Disease?International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with Parkinson's disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota. The present study investigated the effect of rifaximin on gut microbiota and inflammation status in PD. The study examined the effect of long-term rifaximin treatment on in vivo transgenic PD mice (MitoPark) and short-term rifaximin treatment on patients with PD. Rifaximin treatment caused a significant change in gut microbiota in the transgenic PD mice; in particular, it reduced the relative abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.